Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2006-03-28
2006-03-28
Falk, Anne-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S002600
Reexamination Certificate
active
07018979
ABSTRACT:
Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel agonist (other than bradykinin or a bradykinin analog), such as NS-1619,1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levcromakalim, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel agonist together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.
REFERENCES:
patent: 5112596 (1992-05-01), Malfroy-Camine
patent: 5124146 (1992-06-01), Neuwelt
patent: 5215985 (1993-06-01), Murphy et al.
patent: 5234947 (1993-08-01), Cherksey
patent: 5256688 (1993-10-01), Grover et al.
patent: 5262419 (1993-11-01), Aberg et al.
patent: 5268164 (1993-12-01), Kozarich et al.
patent: 5314887 (1994-05-01), Aldrich et al.
patent: 5399587 (1995-03-01), Garcia et al.
patent: 5416097 (1995-05-01), Erhardt et al.
patent: 5434137 (1995-07-01), Black
patent: 5518499 (1996-05-01), Agar
patent: 5527527 (1996-06-01), Friden
patent: 5527778 (1996-06-01), Black
patent: 5578599 (1996-11-01), Diani et al.
patent: 5604198 (1997-02-01), Poduslo et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5677344 (1997-10-01), Greenfield et al.
patent: 5679706 (1997-10-01), D'Alonzo et al.
patent: 5686416 (1997-11-01), Kozarich et al.
patent: 5695751 (1997-12-01), Friedman et al.
patent: 5760230 (1998-06-01), Schohe-Loop et al.
patent: 5767160 (1998-06-01), Kaesemeyer
patent: 5869509 (1999-02-01), Romine et al.
patent: 5922735 (1999-07-01), Sit et al.
patent: 0 351 767 (1990-01-01), None
patent: 0 555 681 (1993-08-01), None
patent: 0 575 749 (1993-12-01), None
patent: WO 91/16355 (1991-10-01), None
patent: WO 97/31654 (1997-09-01), None
patent: WO 00/23102 (2000-04-01), None
Sabate, et al., 1996. Clinical Neuroscience, vol. 3, pp. 317-321.
Adeagbo, A.S.,1-Ethyl-2-benzimidazolinone stimulates endothelial K(Ca)Channels and nitric oxide formation in rat mesenteric vessels, Eur. J./ Pharmacol, 379(2-3):151-9 (Aug. 27, 1999). Abstract Only.
Akar, F., et al.,Protective effect of cromakalim and diazoxide, and proulcerogenic effect of glibenclamide on indomethacin-induced gastric injury, Eur. J. Pharmacol, 374(3):461-70 (Jun. 25, 1999). Abstract Only.
Andrade, S.P., et al.,Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors, Int. J. Exp. Pathol, 79(6):425-32 (Dec. 1998). Abstract Only.
Brian, J.E., Jr., et al.,Recent insights into the regulation of cerebral circulation, Clin. Exp. Pharmacol Physiol, 23(6-7):449-57 (Jun.-Jul. 1996). Abstract Only.
Brismar, T., et al.,Mechanism of high K+ and TI+ uptake in cultured human glioma cells, Cell Mol. Neurobiol, 15(3):351-60 (Jun. 1995). Abstract Only.
Brismar, T., et al.,Thallium-201 uptake relates to membrane potential and potassium permeability in human glioma cells, Brain Res., 500(1-2):30-6 (Oct. 23, 1989). Abstract Only.
Burg, M.A., et al.,NG2 proteoglycan-binding peptides target tumor neovasculature, Cancer Res., 59(12):2869-74 (Jun. 15, 1999). Abstract Only.
Burrows, F. J., et al.,Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature, Proc. Natl. Acad. Science U.S.A., 90(19):8996-9000 (Oct. 1, 1993). Abstract Only.
Butt, A.M.,Effect of inflammatory agents on electrical resistance across the blood-brain barrier in pial microvessels of anaesthetized rats, Brain Res., 696(1-2):145-50 (Oct. 23, 1995). Abstract Only.
Butt, A.M., et al.,Effect of histamine and antagonists on electrical resistance across the blood-brain barrier in rat brain-surface microvessels, Brain Res., 569(1):100-5 (Jan. 8, 1992). Abstract Only.
Cai, S., et al.,Single-Channel characterization of the pharmacological properties of the K(Ca2+)channel of intermediate conductance in bovine aortic endothelial cells, J. Membr. Biol., 163(2):147-58 (May 15, 1998). Abstract Only.
Chang, S.S., et al.,Five different anti-prostate-specific membrane antigen(PSMA)antibodies confirm PSMA expression in tumor-associated neovasculature, Cancer Res., 59(13):3192-8 (Jul. 1, 1999). Abstract Only.
Chaplin, D.J., et al.,Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate, Anticancer Res., 19(1A):189-95 (Jan.-Feb. 1999). Abstract Only.
Chassande, O., et al.,The Na+/K+/Cl- cotransport in C6 glioma cells, Properties and role in volume regulation, Eur. J. Biochem., 171(3)425-33 (Feb. 1, 1988). Abstract Only.
Chess-Williams, R., et al., In vitroinvestigation of the bladder-vascular selectivity of levcromakalim and YM934 in human tissues, BJU Int., 83(9):1050-4 (Jun. 1999). Abstract Only.
Dark, G.G., et al.,Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature, Cancer Res., 57(10):1829-34 (May 15, 1997). Abstract Only.
Denekamp, J., et al.,Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? Adv. Enzyme Regul., 38:281-99 (1998). Abstract Only.
Desai, S.B., et al.,Tumor angiogenesis and endothelial cell modulatory factors, J. Immunother, 22(3):186-211 (May 1999). Abstract Only.
D'hahan, N., et al.,A transmembrane domain of the sulfonylurea receptor mediates activation of ATP-sensitive K(+)channels by K(+)channel openers, Mol. Pharmacol, 56(2):308-15 (Aug. 1999). Abstract Only.
Duda, T.,Mutations in the Rod Outer Segment Membrane Guanylate Cyclase in a Cone-Rod Dystrophy Cause Defects in Calcium Signaling, Biochemistry, 38(42):13912-13919 (Oct. 19, 1999). Abstract Only.
Faraci, F.M., et al.,Responses of cerebral arterioles to N-methyl-D-aspartate and activation of ATP-sensitive potassium channels in old rats, Brain Res., 654(2):349-51 (Aug. 22, 1994). Abstract Only.
Faraci, F.M., et al.,Potassium channels and the cerebral circulation, Clin. Exp. Pharmacol Physiol, 23(12):1091-5 (Dec. 1996). Abstract Only.
Friebe, A., et al.,Mechanism of YC-1-induced activation of soluble guanylyl cyclase, Mol. Pharmacol, 53(1):123-7 (Jan. 1998). Abstract Only.
Goldstein, G. W., et al., In vitrostudies of the blood-brain barrier using isolated brain capillaries and cultured endothelial cells, Ann. N.Y. Acad. Science, 481:202-13 (1986). Abstract Only.
Harland, S. P., et al.,Expression of enthothelin(A)receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707, Neurosurgery, 43(4):890-8; discussion 898-9 (Oct. 1998). Abstract Only.
Holland, M., et al.,Effects of the BKCa channel activator, NS1619, on rat cerebral artery smooth muscle, Br. J. Pharmacol, 117(1):119-29 (Jan. 1996). Abstract Only.
Jain, R. K.,Vascular and interstitial barriers to delivery of therapeutic agents in tumors, Cancer Metastasis Rev., 9(3):253-66 (Nov. 1990). Abstract Only.
Keep, R. F., et al.,Potassium transport at the blood-brain and blood-CSF barriers, Adv. Exp. Med. Biol., 331:43-54 (1993). Abstract Only.
Konoshita, H., et al.,Differential effects of lidocaine and mexiletine on relaxations to ATP-sensitive K+ channel openers in rat aortas, Anesthesiology, 90(4):1165-70 (Apr. 1999). Abstract Only.
Kitazono, T., et al.,Role of potassium channels in cerebral blood vessels, Stroke, 26(9):1713-23 (Sep. 1995). Abstract Only.
Lee, Y.S., et al., In vitroantitumor activity of cromakalim in human brain tumor cells, Pharmacology, 49(2):69-74 (Aug. 1994). Abstract Only.
Manor, D., et al.,Interactions among calcium compartments in C6 rat glioma cells; involvement of potassium channels, J. Physiol.(Lond.), 478(Pt.2):251-63 (Jul. 15, 1994). Abstract Only.
Miller, T.R., et al.,Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 huma medulloblastoma cel
Black Keith L.
Ningaraj Nagendra S.
Cedars-Sinai Medical Center
Falk Anne-Marie
King & Spalding LLP
Knowles, Esq. Sherry M.
LandOfFree
Method for using potassium channel agonists for delivering a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for using potassium channel agonists for delivering a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for using potassium channel agonists for delivering a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3584026